Monoamine transporter

Monoamine transporters are proteins embedded in the membrane of neurons that have released a monoamine neurotransmitter. Their function is termination: once serotonin, dopamine, or norepinephrine has crossed the synapse and bound to its target receptors, the corresponding transporter — SERT, DAT, or NET — pumps it back into the releasing cell, ending the signal.

All three belong to the same molecular family (SLC6) and operate by the same general principle: coupling the movement of a neurotransmitter to the flow of sodium ions down their electrochemical gradient. Because they sit at the endpoint of every monoamine signal, they are one of the main leverage points where psychoactive drugs act.

How it works · its role

When a neuron fires, monoamines flood the synapse; the transporters then begin pulling them back across the membrane. This reuptake is not passive — it is driven by the sodium and chloride gradients the neuron maintains, effectively using ionic energy to run the protein as a pump.

Drugs interact with transporters in two mechanistically distinct ways. Reuptake inhibitors bind to the transporter's recognition site without being carried across, physically blocking reuptake so the monoamine lingers longer than it otherwise would. Substrate-type releasers are taken up by the transporter and cause it to run in reverse, actively pumping stored monoamines out of the cell even without a firing event — a process that can produce a much larger, more abrupt release than inhibition alone.

Relevance to substances & effects

A compound's relative affinity across the three transporters is one of the primary determinants of its subjective character. Substances that act predominantly at DAT — cocaine, methylphenidate — produce alertness, motivation, and elevated mood through increased synaptic dopamine. Compounds that combine strong SERT activity with DAT and NET activity, such as MDMA, shift the profile toward emotional warmth, closeness, and reduced defensiveness.

The transporter selectivity also explains how broader drug classes differ. SSRIs target SERT almost exclusively, producing gradual mood changes over weeks. Amphetamines act mainly as releasing agents at DAT and NET, driving more acute stimulant effects. Tricyclic antidepressants block both SERT and NET, which contributes to their side-effect profile alongside their therapeutic action.

Because transporters are the primary route for clearing monoamines from the synapse, anything that blocks them raises the effective concentration of whichever monoamine is present. Combining two reuptake-blocking agents, or adding a reuptake inhibitor to a monoamine oxidase inhibitor, stacks two separate mechanisms of accumulation — an important factor in several high-severity drug interactions flagged across the encyclopedia.